View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	Apr. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	0001095981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		61,622,799
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 5,902	$ 9,550
Accounts receivable, net of reserves of $167 in both 2018 and 2017	769	145
Restricted cash	40	675
Inventories, net	3,188	3,183
Other current assets	837	1,311
Total current assets	10,736	14,864
Property and equipment, net	2,907	3,052
Other assets	2,182	2,570
Intangibles, net	6,895	7,207
Goodwill	3,922	3,922
Total assets	26,642	31,615
Current liabilities:
Accounts payable and accrued expenses	4,150	4,790
Current portion of long-term obligations, net of discount	13,729	13,624
Total current liabilities	17,879	18,414
Deferred revenues	178	94
Long-term deferred rent and other	105	107
Total liabilities	18,162	18,615
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 23,500 shares issued; 1,203 and 2,431 shares outstanding in 2018 and 2017, respectively
Common stock, $0.001 par value; 75,000,000 shares authorized; 61,613,798 and 57,825,729 shares issued and outstanding in 2018 and 2017, respectively	62	58
Additional paid-in capital	413,470	413,304
Accumulated other comprehensive income	1,106	1,387
Accumulated deficit	(406,158)	(401,749)
Total stockholders’ equity	8,480	13,000
Total liabilities and stockholders’ equity	$ 26,642	$ 31,615

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Accounts receivable, reserves	$ 167	$ 167
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	23,500	23,500
Preferred stock, shares outstanding (in shares)	1,203	2,431
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	61,613,798	57,825,729
Common stock, shares outstanding (in shares)	61,613,798	57,825,729

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Product revenues	$ 731	$ 591
Cost of product revenues	273	410
Amortization of intangible assets	306	306
Gross (loss) profit	152	(125)
Development revenues:
Government contracts and other	917	1,018
Total development revenues	917	1,018
Operating expenses:
Research and development	2,499	3,289
Sales and marketing	678	939
General and administrative	2,244	2,108
Total operating expenses	5,421	8,022
Operating loss	(4,352)	(7,129)
Other income (expense):
Interest income	14	11
Interest expense	(423)	(591)
Other income, net	352	165
Total other expense	(57)	(415)
Net loss	$ (4,409)	$ (7,544)
Basic and diluted net loss per share	$ (0.07)	$ (0.33)
Basic and diluted weighted average shares used in calculating net loss per share	60,177,911	22,736,366
Comprehensive loss:
Net loss	$ (4,409)	$ (7,544)
Other comprehensive loss – foreign currency translation adjustments	(281)	(60)
Comprehensive loss	(4,690)	(7,604)
Azaya Therapeutics, Inc. [Member]
Operating expenses:
In process research and development acquired from Azaya Therapeutics	$ 0	$ 1,686

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (4,409)	$ (7,544)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	497	442
Amortization of deferred financing costs and debt discount	105	219
Provision for expired inventory	326	340
Share-based compensation expense	143	199
Loss on asset disposal	22	2
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	(747)	335
Inventories	141	7
Other current assets	301	(65)
Other assets	(24)	24
Accounts payable and accrued expenses	(556)	(484)
Deferred revenues	84	12
Long-term deferred rent	(2)	0
Net cash used in operating activities	(4,119)	(4,827)
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	(53)	(5)
Net cash used in investing activities	(53)	(1,163)
Cash flows from financing activities:
Principal payments on long-term obligations	0	(1,770)
Proceeds from sale of common stock, net	(150)	1,435
Net cash used in financing activities	(150)	(335)
Effect of exchange rate changes on cash and cash equivalents	39	20
Net decrease in cash and cash equivalents	(4,283)	(6,305)
Cash, cash equivalents, and restricted cash at beginning of period	10,225	12,910
Cash, cash equivalents, and restricted cash at end of period	5,942	6,605
Cash paid during period for:
Interest	311	384
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common stock	4	0
Azaya Therapeutics, Inc. [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
In process research and development acquired from Azaya Therapeutics	0	1,686
Cash flows from investing activities:
Purchases of property and equipment /long-lived assets	0	(1,158)
Supplemental schedule of non-cash investing and financing activities:
Liabilities assumed in payment for assets acquired	0	279
Common stock issued in payment for the assets acquired	$ 0	$ 2,311

Basis of Presentation and New Accounting Standards

3 Months Ended

Mar. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation and New Accounting Standards

1.	Basis of Presentation and New Accounting Standards

Our accompanying unaudited consolidated condensed financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at December 31, 2017, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 9, 2018.

Reclassifications

Certain amounts in prior periods have been reclassified to conform with current period presentation.

Recently Issued and Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases. Under this new guidance, at the commencement date, lessees will be required to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted. We are currently evaluating the impact that this standard will have on our consolidated financial statements.

In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, to simplify how all entities assess goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As amended, the goodwill impairment test will consist of one step comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements.

Recently Adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. We have adopted the standards beginning this first quarter of 2018 using the modified retrospective method. Overall, the timing or amounts related to the revenue recognition under the new standards did not differ from our previously applied revenue recognition policy. Our product revenues are recognized at a point in time, which is when control transfers to the customer. We have made an accounting policy election to treat shipping and handling activities that occur after the customer obtains control of the goods as fulfillment costs. There was no cumulative effect of applying the new standards as of the adoption date on January 1, 2018.

In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The adoption of this standard, in the first quarter of 2018, changed the presentation of our statement of cash flows to include our restricted cash balance with the non-restricted cash balances. The new guidance did not have a material impact on the Company's consolidated financial statements. Cash, cash equivalents, and restricted cash reported on the Consolidated Condensed Statements of Cash Flows includes restricted cash of $0.4 million, $0.4 million, $0.7 million, and $40 thousand as of December 31, 2016, March 31, 2017, December 31, 2017 and March 31, 2018, respectively.

Liquidity

3 Months Ended

Mar. 31, 2018

Liquidity [Abstract]

Liquidity

We incurred net losses of $4.4 million for the three months ended March 31, 2018, and $7.5 million for the three months ended March 31, 2017. We have an accumulated deficit of $406.2 million as of March 31, 2018. Additionally, we have used net cash of $4.1 million and $4.8 million to fund our operating activities for the three months ended March 31, 2018 and 2017, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

Further, the Loan and Security Agreement, with Oxford Finance, LCC (“Oxford”), as further described in Note 4, requires maintaining a minimum of $1.5 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Loan and Security Agreement. Based on our cash and cash equivalents on hand of approximately $5.9 million at March 31, 2018, the Company estimates that it will need to raise additional capital and/or obtain a waiver or restructure the Loan and Security Agreement in the near term to avoid defaulting under its $1.5 million minimum cash/cash equivalents covenant.

To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed 2017 Rights Offering, our Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), the Loan and Security Agreement and gross profits. We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations. Our inability to raise additional cash will have a material and adverse impact on operations and will cause us to default on our loan.

On December 22, 2016, we entered into a purchase agreement and a registration rights agreement, with Lincoln Park pursuant to which we have the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $20.0 million of shares of the Company’s common stock over the 30-month period following March 31, 2017, subject to the satisfaction of certain conditions. See Note 11 for further discussion on the Lincoln Park agreement.

On April 11, 2017, we entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC “Maxim”) relating to the issuance and sale of 8.6 million shares of our common stock, par value $0.001 per share. The price to the public in this offering was $1.10 per share. Maxim agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.0395 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on April 17, 2017. In addition, under the terms of the Underwriting Agreement, we granted Maxim a 45-day option to purchase up to 944,000 additional shares of common stock. On May 31, 2017, Maxim exercised their overallotment option and purchased 849,000 shares at $1.10 per share. The net proceeds to us were $0.8 million, after deducting underwriting costs and offering expenses payable by us.

On September 5, 2017, we received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided a period of 180 calendar days, or until March 5, 2018, in which to regain compliance. We were granted an additional compliance period of 180 calendar days, or until September 4, 2018, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period.

On November 28, 2017, we closed a rights offering originally filed under a Form S-1 registration statement in August 2017 (“2017 Rights Offering”). Pursuant to the 2017 Rights Offering, the Company sold an aggregate of 10,000 units consisting of a total of 10,000 shares of Series B Convertible Preferred Stock, immediately convertible into approximately 30,000,000 shares of common stock and 18,000,000 warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.3333 per share, resulting in total net proceeds to the Company of $8.8 million. These warrants only become exercisable upon stockholder approval.

We continue to seek additional capital through product revenues, strategic transactions, including extension opportunities under our awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, we will at a minimum need to significantly reduce or curtail our research and development and other operations, and this could negatively affect our ability to achieve corporate growth goals.

Should we be unable to raise additional cash from outside sources, this will have a material adverse impact on our operations.

The accompanying consolidated condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

Long-term Debt

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Long-term Debt

4.	Long-term Debt

On May 29, 2015, we entered into the Loan and Security Agreement, dated May 29, 2015, with Oxford, pursuant to which it funded an aggregate principal amount of $17.7 million (“Term Loan”), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, we were previously required to make interest only payments through June 1, 2016 and thereafter we were required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June 1, 2019, the maturity date. On February 23, 2016, we received an acknowledgement and agreement from Oxford related to the positive data on our U.S. ACT-OA clinical trial. As a result, pursuant to the Loan and Security Agreement, the period for which we are required to make interest-only payments was extended from July 1, 2016 to January 1, 2017. All unpaid principal and interest with respect to the Term Loan is due and payable in full on June 1, 2019. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, we are required to make a final payment in an aggregate amount equal to approximately $1.1 million. In connection with the Term Loan, on May 29, 2015, we issued to Oxford warrants to purchase an aggregate of 94,441 shares of our common stock at an exercise price of $10.35 per share. These warrants became exercisable as of November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified and its respective fair value was recorded as a discount to the debt.

On September 20, 2017, we entered into an amendment to the Term Loan, pursuant to which, among other things, Oxford and the Lenders agreed to reduce the minimum liquidity covenant level originally at $5 million to $1.5 million. The amendment also extended the interest-only period under the Loan Agreement through August 1, 2018, as the Company successfully closed on a financing and received unrestricted net cash proceeds in excess of $5 million on or before December 29, 2017.

The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving certain liquidity level when the total principal outstanding under the Loan Agreement is less than $3 million. As of March 31, 2018, we were in compliance with all of the debt covenants under the Loan and Security Agreement.

Our interest expense for the three months ended March 31, 2018 and 2017 was $0.4 million and $0.6 million, respectively. Interest expense is calculated using the effective interest method, therefore it is inclusive of non-cash amortization in the amount of $0.1 million and 0.2 million, respectively, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment.

The Term Loan Agreement contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in our business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by us or a declaration of material adverse change by our lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Term Loan, which could materially harm our financial condition. As of March 31, 2018, we were in compliance with all covenants under the Term Loan and have not received any notification or indication from the Lenders to invoke the material adverse change clause. However, due to our current cash flow position and the substantial doubt about our ability to continue as a going concern, the entire principal amount of the Term Loan has been reclassified to short-term. We will continue to evaluate the debt classification on a quarterly basis and evaluate for reclassification in the future should our financial condition improve.

Revenue Recognition

3 Months Ended

Mar. 31, 2018

Revenue Recognition [Abstract]

Revenue Recognition

5.	Revenue Recognition

Product Sales

Our revenue is generated primarily from the sale of products. Product revenue primarily consists of sales of Celution devices and consumables for commercial and research purposes.

The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue.

Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred.

The following table represents revenue by product (in thousands):

	March 31, 2018		March 31, 2017
Consumable	$	559	$	509
Device		94		30
Other products		78		52
	$	731	$	591

Product revenues, classified by geographic location, are as follows (in thousands):

	Three months ended
	March 31, 2018					March 31, 2017
	Product Revenues		% of Total			Product Revenues		% of Total
Americas	$	45		6	%	$	148		25	%
Japan		578		79	%		320		54	%
EMEA		90		12	%		112		19	%
Asia Pacific		18		3	%		11		2	%
Total product revenues	$	731		100	%	$	591		100	%

Concentration of Significant Customers

Four direct customers comprised 66% of our revenue recognized for the three months ended March 31, 2018. Three direct customers, two distributors and one licensee accounted for 75% of total outstanding accounts receivable (excluding receivables from the Biomedical Advanced Research Development Authority, a division of the U.S. Department of Health and Human Services (“BARDA”)) as of March 31, 2018.

Three direct customers comprised 51% of our revenue recognized for the three months ended March 31, 2017. Two direct customers accounted for 53% of total outstanding accounts receivable as of March 31, 2017.

Development Revenue

We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA which is outside of the scope of the new revenue recognition guidance. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contracts and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $0.9 million in development revenue for the three months ended March 31, 2018, as compared to $1.0 million for the three months ended March 31, 2017.

Stockholders' Equity

3 Months Ended

Mar. 31, 2018

Stockholders Equity Note [Abstract]

Stockholders' Equity

11.	Stockholders’ Equity

Preferred Stock

The Company has authorized 5 million shares of preferred stock, par value $0.001 per share. The Company’s Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock that had been issued at December 31, 2017 and 2016, none of which were outstanding as of either date. All outstanding shares of the Series A 3.6% Convertible Preferred Stock were converted into common stock by the first quarter of 2015 at the option of the holders.

On November 27, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.001 per share, designated as the “Series B Convertible Preferred Stock”. The number of shares initially constituting the Series B Convertible Preferred Stock was set at 10,000 shares. Pursuant to a registration statement on Form S-1, originally filed on August 14, 2017, as amended, and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on November 2, 2017, and related prospectus (as supplemented), the Company registered and distributed to holders of its common stock, at no charge, non-transferable subscription rights to purchase up to an aggregate of 10,000 units consisting of 10,000 shares of Series B Convertible Preferred Stock and 18 million warrants, with each warrant exercisable for one common stock at an exercise price of $0.3333 per share for 30 months from the date of issuance at any time after the date the stockholder approval to increase our authorized common stock share count. Pursuant to the 2017 Rights Offering, which closed on November 28, 2017, the Company sold an aggregate of 10,000 units, resulting in total net proceeds to the Company of approximately $8.8 million. The Company applied to list the warrants on Nasdaq under the symbol “CYTXS” to meet the minimum listing criteria to be accepted for listing on Nasdaq subsequent to attainment of stockholder approval. Based on the relevant authoritative accounting guidance, the warrants were equity classified at the issuance date. The warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration if the Company’s common stock closes above $0.833 per share for 10 consecutive trading days.

The fair value of the common stock into which the Series B Convertible Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a dividend to the preferred stockholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common stockholders. We recorded a deemed dividend within additional paid-in capital of $4.0 million for the year ended December 31, 2017, related to a beneficial conversion feature included in the issuance of our Series B Convertible Preferred Stock. Approximately 88% of the outstanding shares of the Series B Convertible Preferred Stock were converted into common stock by March 31, 2018 at the option of the holders.

Holders of Series B Convertible Preferred Stock shall be entitled to receive dividends in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of Common Stock. Except as otherwise provided in the Certificate of Designation or as otherwise required by law, the Series B Convertible Preferred Stock has no voting rights. Upon Cytori’s liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B Convertible Preferred Stock will be entitled to receive out of Cytori’s assets, whether capital or surplus, an amount equal to the $1,000 stated value per share for each share of Series B Convertible Preferred Stock before any distribution or payment shall be made to the holders of any junior securities. Cytori is not obligated to redeem or repurchase any shares of Series B Convertible Preferred Stock. Series B Convertible Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.

Common Stock

On December 22, 2016, the Company entered into a Purchase Agreement (the “Lincoln Park Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”) pursuant to which the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $20.0 million in amounts of shares, of the Company’s common stock, over the 30-month period following March 30, 2017. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 100,000 shares of common stock on any business day but in no event will the amount of a single Regular Purchase (as defined in the Lincoln Park Purchase Agreement) exceed $1.0 million. The purchase price of shares of common stock related to the Regular Purchases will be based on the prevailing market prices of such shares at the time of sales. The Company’s sales of shares of common stock to Lincoln Park under the Lincoln Park Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 9.99% of the then outstanding shares of the common stock. There are no trading volume requirements or restrictions under the Lincoln Park Purchase Agreement. There is no upper limit on the price per share that Lincoln Park must pay for common stock under a Regular Purchase or an accelerated purchase and in no event will shares be sold to Lincoln Park on a day our closing price is less than the floor price of $0.50 per share as set forth in the Purchase Agreement. On December 22, 2016, we issued to Lincoln Park 127,419 shares of common stock with a market value on the date of issuance of approximately $0.2 million as commitment shares in consideration for entering into the Lincoln Park Purchase Agreement. The Company will issue up to an additional 382,258 shares of common stock on a pro rata basis to Lincoln Park only as and when shares are sold under the Lincoln Park Purchase Agreement to Lincoln Park. Through March 31, 2018, the Company sold a total of 1,994,717 shares under the Lincoln Park Purchase Agreement, for proceeds of approximately $1.7 million.

On April 11, 2017, we entered into an underwriting agreement with Maxim relating to the issuance and sale of 8.6 million shares of our common stock, par value $0.001 per share. The price to the public in the offering is $1.10 per share. Maxim agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.0395 per share. The net proceeds to us from the offering were approximately $8.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on April 17, 2017. In addition, under the terms of the underwriting agreement, we granted Maxim a 45-day overallotment option to purchase up to 944,000 additional shares of common stock. On May 31, 2017, Maxim exercised their overallotment option and purchased 849,000 shares at $1.10 per share. The net proceeds to us were $0.8 million, after deducting underwriting costs and offering expenses payable by us.

Basis of Presentation and New Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and New Accounting Standards	Our accompanying unaudited consolidated condensed financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. Our consolidated condensed balance sheet at December 31, 2017 has been derived from the audited financial statements at December 31, 2017, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Cytori Therapeutics, Inc., and our subsidiaries (collectively, the “Company”) have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. These financial statements should be read in conjunction with the consolidated financial statements and notes therein included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 9, 2018.
Reclassifications	Reclassifications Certain amounts in prior periods have been reclassified to conform with current period presentation.
Recently Issued and Recently Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases. Under this new guidance, at the commencement date, lessees will be required to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. This guidance is not applicable for leases with a term of 12 months or less. The new standard is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted. We are currently evaluating the impact that this standard will have on our consolidated financial statements. In February 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, to simplify how all entities assess goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As amended, the goodwill impairment test will consist of one step comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements. Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services. ASU 2014-09 and all subsequent amendments (collectively, the “new standards”) may be applied using either the full retrospective method, in which case the standard would be applied to each prior reporting period presented, or the modified retrospective method, in which case the cumulative effect of applying the standard would be recognized at the date of initial application. We have adopted the standards beginning this first quarter of 2018 using the modified retrospective method. Overall, the timing or amounts related to the revenue recognition under the new standards did not differ from our previously applied revenue recognition policy. Our product revenues are recognized at a point in time, which is when control transfers to the customer. We have made an accounting policy election to treat shipping and handling activities that occur after the customer obtains control of the goods as fulfillment costs. There was no cumulative effect of applying the new standards as of the adoption date on January 1, 2018. In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash, which requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The adoption of this standard, in the first quarter of 2018, changed the presentation of our statement of cash flows to include our restricted cash balance with the non-restricted cash balances. The new guidance did not have a material impact on the Company's consolidated financial statements. Cash, cash equivalents, and restricted cash reported on the Consolidated Condensed Statements of Cash Flows includes restricted cash of $0.4 million, $0.4 million, $0.7 million, and $40 thousand as of December 31, 2016, March 31, 2017, December 31, 2017 and March 31, 2018, respectively.
Use of Estimates	The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, measuring expense related to our in-process research and development acquisition, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.
Revenue Recognition	The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue. Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred.

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2018

Revenue Recognition [Abstract]

Revenue by Product

The following table represents revenue by product (in thousands):

	March 31, 2018		March 31, 2017
Consumable	$	559	$	509
Device		94		30
Other products		78		52
	$	731	$	591

Product Revenues, Classified by Geographic Location

Product revenues, classified by geographic location, are as follows (in thousands):

	Three months ended
	March 31, 2018					March 31, 2017
	Product Revenues		% of Total			Product Revenues		% of Total
Americas	$	45		6	%	$	148		25	%
Japan		578		79	%		320		54	%
EMEA		90		12	%		112		19	%
Asia Pacific		18		3	%		11		2	%
Total product revenues	$	731		100	%	$	591		100	%

Liquidity (Details) - USD ($)						3 Months Ended
Liquidity (Details) - USD ($)	Nov. 28, 2017	Sep. 05, 2017	May 31, 2017	Apr. 11, 2017	Dec. 22, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Liquidity [Line Items]
Net loss						$ 4,409,000	$ 7,544,000
Accumulated deficit						406,158,000		$ 401,749,000
Net cash used in operating activities						4,119,000	4,827,000
Cash and cash equivalents						5,902,000		$ 9,550,000
Minimum cash/cash equivalents covenant						$ 1,500,000
Common stock issued (in shares)	10,000
Common stock, par value (in dollars per share)						$ 0.001		$ 0.001
Proceeds from sale of common stock, net						$ (150,000)	$ 1,435,000
Proceeds from issuance warrants	$ 8,800,000
Series B Convertible Preferred Stock [Member]
Liquidity [Line Items]
Common stock issued (in shares)	30,000,000
Number of shares callable by warrants (in shares)	18,000,000
Nasdaq Stock Market LLC [Member]
Liquidity [Line Items]
Number of consecutive business days no longer able to meet the required closing bid price of common stock		30 days
Minimum bid price of common stock required for Nasdaq listing rule		$ 1
Grace period provided with minimum bid price for Nasdaq listing rule		180 days
Grace date for minimum bid price requirement for Nasdaq listing		Mar. 05, 2018
Common stock minimum bid price required to regain compliance		$ 1
Number of consecutive business days required to regain compliance		10 days
Additional grace period provided with minimum bid price to regain compliance		180 days
Date to regain compliance after meeting continued listing requirement		Sep. 04, 2018
Common Stock [Member]
Liquidity [Line Items]
Common stock issued (in shares)	10,000
Share issued, price per share				$ 1.10
Number of shares callable by warrants (in shares)						1
Warrant exercise price (in dollars per share)	$ 0.3333
Common Stock [Member] \| Maxim Group LLC [Member]
Liquidity [Line Items]
Common stock issued (in shares)			849,000	8,600,000
Common stock, par value (in dollars per share)				$ 0.001
Share issued, price per share			$ 1.10	$ 1.0395
Proceeds from sale of common stock, net			$ 800,000	$ 8,700,000
Closing of offering date				Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter				45 days
Additional shares of common stock				944,000
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member]
Liquidity [Line Items]
Common stock issued, value					$ 20,000,000
Period exercisable from the date of issuance					30 months
Minimum [Member]
Liquidity [Line Items]
Unrestricted cash and cash equivalents						$ 1,500,000

Long-term Debt (Details) - USD ($)			3 Months Ended
Long-term Debt (Details) - USD ($)	Dec. 29, 2017	May 29, 2015	Mar. 31, 2018	Mar. 31, 2017	Sep. 20, 2017
Debt Instrument [Line Items]
Minimum liquidity covenant			$ 1,500,000
Interest expense			423,000	$ 591,000
Non-cash amortization			$ 100,000	$ 200,000
LIBOR [Member] \| Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate		1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination Date			May 29, 2015
Original Loan Amount		$ 17,700,000
Basis variable rate		7.95%
Maturity date			Jun. 01, 2019
Fees amount associated with loan		$ 1,100,000
Number of shares callable by warrants (in shares)		94,441
Warrant exercise price (in dollars per share)		$ 10.35
Date from which warrants are exercisable			Nov. 30, 2015
Warrant expiration date			May 29, 2025
Minimum liquidity covenant		$ 5,000,000			$ 1,500,000
Extended interest-only period			Aug. 01, 2018
Debt instrument, interest-only period			The amendment also extended the interest-only period under the Loan Agreement through August 1, 2018, as the Company successfully closed on a financing and received unrestricted net cash proceeds in excess of $5 million on or before December 29, 2017.
Net proceeds excess receives from unrestricted cash	$ 5,000,000
Debt instrument, covenant compliance			we were in compliance with all of the debt covenants under the Loan and Security Agreement.
Minimum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Interest rate		8.95%
Maximum [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Original Loan Amount			$ 3,000,000

Commitments and Contingencies (Details) - USD ($) $ in Thousands			3 Months Ended
	Feb. 27, 2017	Jan. 27, 2017	Mar. 31, 2018	Apr. 27, 2018	Dec. 31, 2017
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease	63 months
Lease commencement date	Jan. 01, 2018
Buy-out of obligations lease	$ 600
Common stock, aggregate amount			$ 62		$ 58
Lorem Vascular [Member] \| Subsequent Event [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Percentage of common stock to be purchased				5.00%
Common stock, aggregate amount				$ 5,000
Japan Lease [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Initial term of lease		61 months
Lease commencement date			Apr. 15, 2017
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation, due in next twelve months			$ 2,200
Contractual obligation			3,900
Roche Diagnostics Corporation [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligation			4,000
Purchase obligation, due in next twelve months			$ 1,000

Asset Purchase Agreement with Azaya Therapeutics - Additional Information (Details) - Azaya Therapeutics, Inc. [Member] $ in Thousands		3 Months Ended
	Feb. 15, 2017 USD ($) Candidate shares	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
Total consideration	$ 4,300
Fair value of the common stock issued	2,300
Assumed liabilities	1,800
Acquisition costs	200
In process research and development expense	1,700	$ 0	$ 1,686
Asset Purchase Agreement
Business Acquisition [Line Items]
Book value of tangible assets acquired	$ 3,000
Common stock, shares issued \| shares	1,173,241
Common stock, shares issued after closing date \| shares	879,931
Common stock deposited in escrow \| shares	293,310
Obligation to pay on existing payables assumed	$ 1,800
Existing payables, paid during the period				$ 1,800
Asset Purchase Agreement \| IPR&D [Member]
Business Acquisition [Line Items]
Number of drug candidates acquired \| Candidate	2

Stockholders' Equity - Preferred Stock (Details) - USD ($)			3 Months Ended	12 Months Ended
	Nov. 28, 2017	Nov. 02, 2017	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Nov. 27, 2017
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)			5,000,000	5,000,000
Preferred stock, par value (in dollars per share)			$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)			23,500	23,500
Preferred stock, shares outstanding (in shares)			1,203	2,431
Common stock issued (in shares)	10,000
Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)			1
Warrant exercise price (in dollars per share)	$ 0.3333
Common stock issued (in shares)	10,000
2017 Rights Offering [Member]
Preferred Stock [Abstract]
Charge on Non Transferable Subscription Rights		$ 0
Number of shares callable by warrants (in shares)		10,000
Warrant exercise price (in dollars per share)		$ 0.3333
Period exercisable from the date of issuance			30 months
Common stock issued (in shares)	10,000
Gross proceeds from private placement of stock	$ 8,800,000
Redemption price of warrant prior to expiration			$ 0.01
Common stock price per share for warrant redemption			$ 0.833
Number of consecutive trading days for warrant redemption			10 days
2017 Rights Offering [Member] \| Warrant [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		18
2017 Rights Offering [Member] \| Common Stock [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		1
Series A Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)				13,500	13,500
Convertible preferred stock				3.60%	3.60%
Preferred stock, shares outstanding (in shares)				0	0
Series B Convertible Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)						10,000
Preferred stock, par value (in dollars per share)						$ 0.001
Number of shares callable by warrants (in shares)	18,000,000
Common stock issued (in shares)	30,000,000
Percentage of preferred stock converted to common stock			88.00%
Preferred stock, dividend payment terms			Holders of Series B Convertible Preferred Stock shall be entitled to receive dividends in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of Common Stock.
Preferred stock, voting rights			Series B Convertible Preferred Stock has no voting rights.
Preferred stock, dividend preference			Upon Cytori’s liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series B Convertible Preferred Stock will be entitled to receive out of Cytori’s assets, whether capital or surplus, an amount equal to the $1,000 stated value per share for each share of Series B Convertible Preferred Stock before any distribution or payment shall be made to the holders of any junior securities.
Preferred stock, liquidation preference per share			$ 1,000
Series B Convertible Preferred Stock [Member] \| Dividend Paid [Member]
Preferred Stock [Abstract]
Dividends payable				$ 4,000,000
Series B Convertible Preferred Stock [Member] \| 2017 Rights Offering [Member]
Preferred Stock [Abstract]
Number of shares callable by warrants (in shares)		10,000

Stockholders' Equity - Common Stock (Details) - USD ($)					3 Months Ended
Stockholders' Equity - Common Stock (Details) - USD ($)	Nov. 28, 2017	May 31, 2017	Apr. 11, 2017	Dec. 22, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Common Stock [Abstract]
Common stock issued (in shares)	10,000
Proceeds from sale of common stock, net					$ (150,000)	$ 1,435,000
Common stock, par value (in dollars per share)					$ 0.001		$ 0.001
Common Stock [Member]
Common Stock [Abstract]
Common stock issued (in shares)	10,000
Share issued, price per share			$ 1.10
Common Stock [Member] \| Maxim Group LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		849,000	8,600,000
Proceeds from sale of common stock, net		$ 800,000	$ 8,700,000
Common stock, par value (in dollars per share)			$ 0.001
Share issued, price per share		$ 1.10	$ 1.0395
Closing of offering date			Apr. 17, 2017
Number of days granted as option to purchase additional shares of common stock to underwriter			45 days
Additional shares of common stock			944,000
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value				$ 20,000,000
Period exercisable from the date of issuance				30 months
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Purchase Agreement [Member]
Common Stock [Abstract]
Common stock issued, value				$ 200,000
Common stock issued (in shares)				1,994,717
Proceeds from sale of common stock, net				$ 1,700,000
Common Stock [Member] \| Securities Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)				127,419
Trading Volume of Common Shares				0
Common stock issued (in shares)				382,258
Common Stock [Member] \| Maximum [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Purchase Agreement [Member]
Common Stock [Abstract]
Floor price of per share				$ 0.50
Common Stock [Member] \| Maximum [Member] \| Single Regular Purchase [Member] \| Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)				100,000
Common Stock [Member] \| Minimum [Member] \| Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Beneficial ownership percentage of common stock outstanding				9.99%
Common Stock [Member] \| Minimum [Member] \| Single Regular Purchase [Member] \| Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value				$ 1,000,000

Revenue Recognition (Details) $ in Thousands	3 Months Ended
Revenue Recognition (Details) $ in Thousands	Mar. 31, 2018 USD ($) Obligation Customer Distributor Licensee	Mar. 31, 2017 USD ($) Customer
Concentration Risk [Line Items]
Number of performance obligation \| Obligation	1
Payment terms with customers	The Company’s contracts do not involve financing elements as payment terms with customers are less than one year.
Concentration risk percentage	100.00%	100.00%
Development revenue recognized \| $	$ 917	$ 1,018
Customer Concentration Risk [Member] \| Revenue Recognized [Member]
Concentration Risk [Line Items]
Number of customers	4	3
Concentration risk percentage	66.00%	51.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers	3	2
Concentration risk percentage	75.00%	53.00%
Number of distributors \| Distributor	2
Number of licensee \| Licensee	1

Revenue Recognition - Product Revenues, Classified by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Revenues	$ 731	$ 591
Concentration risk percentage	100.00%	100.00%
Americas [Member]
Concentration Risk [Line Items]
Revenues	$ 45	$ 148
Concentration risk percentage	6.00%	25.00%
Japan [Member]
Concentration Risk [Line Items]
Revenues	$ 578	$ 320
Concentration risk percentage	79.00%	54.00%
EMEA [Member]
Concentration Risk [Line Items]
Revenues	$ 90	$ 112
Concentration risk percentage	12.00%	19.00%
Asia Pacific [Member]
Concentration Risk [Line Items]
Revenues	$ 18	$ 11
Concentration risk percentage	3.00%	2.00%

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 695	$ 681
Work in process	557	722
Finished goods	1,936	1,780
Inventory, net	$ 3,188	$ 3,183

Loss per Share (Details) - shares shares in Millions	3 Months Ended
Loss per Share (Details) - shares shares in Millions	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	22.7	4.7
Outstanding Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	21.7
Options and Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)	1.0

Basis of Presentation and New Accounting Standards (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Accounting Standards Update No. 2016-18 [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Restricted cash	$ 40	$ 700	$ 400	$ 400